| Use of guideline-recommended therapies for heart failure in the Medicare population. | |
| | |
MedLine Citation:
|
PMID: 20641116 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Most information about the use of guideline-recommended therapies for heart failure reflects what occurred at discharge after an inpatient stay. HYPOTHESIS: Using a nationally representative, community-dwelling sample of elderly Medicare beneficiaries, we examined how the use of angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and beta-blockers has changed and factors associated with their use. METHODS: Using data from the Medicare Current Beneficiary Survey cost and use files matched with Medicare claims data, we identified beneficiaries for whom a diagnosis of heart failure was reported between January 1, 2000, and December 31, 2004. Data on medications prescribed during the year of cohort entry were based on patient self-report. We used multivariable logistic regression to explore relationships between the use of ACE inhibitors/ARBs and beta-blockers and patient demographic characteristics. RESULTS: From 2000 through 2004, the use of ARBs increased from 12% to 19%, and the use of beta-blockers increased from 30% to 41%. The use of ACE inhibitors remained constant at 45%. Beneficiaries who reported having prescription drug insurance coverage were 32% more likely than other beneficiaries to have filled a prescription for an ACE inhibitor or ARB and 26% more likely to have filled a prescription for a beta-blocker. CONCLUSIONS: Although the use of guideline-recommended therapies for heart failure has increased, it remains suboptimal. |
| | |
Authors:
|
Lisa D DiMartino; Alisa M Shea; Adrian F Hernandez; Lesley H Curtis |
Related Documents
:
|
22854636 - Cardiac events in hypertensive patients with renal artery stenosis treated with renal a... 12368586 - Angiotensin ii receptor blockers in the treatment of heart failure. 18454336 - Ras blockade with arb and ace inhibitors: current perspective on rationale and patient ... 8775936 - Applying the results of large clinical trials in the management of acute myocardial inf... 10415526 - Myocardial response to stress in cardiac hypertrophy and heart failure: effect of antih... 16368356 - Hybrid surgical angiogenesis: omentopexy can enhance myocardial angiogenesis induced by... |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural |
Journal Detail:
|
Title: Clinical cardiology Volume: 33 ISSN: 1932-8737 ISO Abbreviation: Clin Cardiol Publication Date: 2010 Jul |
Date Detail:
|
Created Date: 2010-07-19 Completed Date: 2010-10-26 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7903272 Medline TA: Clin Cardiol Country: United States |
Other Details:
|
Languages: eng Pagination: 400-5 Citation Subset: IM |
Copyright Information:
|
Copyright (c) 2010 Wiley Periodicals, Inc. |
Affiliation:
|
Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina 27715, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adrenergic beta-Antagonists
/
therapeutic use Aged Angiotensin II Type 1 Receptor Blockers / therapeutic use Angiotensin-Converting Enzyme Inhibitors / therapeutic use Cardiovascular Agents / therapeutic use* Drug Prescriptions / statistics & numerical data Drug Utilization / statistics & numerical data Female Guideline Adherence Health Care Surveys Heart Failure / drug therapy* Humans Insurance, Pharmaceutical Services / statistics & numerical data Logistic Models Male Medicare / statistics & numerical data* Physician's Practice Patterns / statistics & numerical data* Practice Guidelines as Topic Risk Assessment Risk Factors Treatment Outcome United States |
| Grant Support | |
ID/Acronym/Agency:
|
R01AG026038/AG/NIA NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Adrenergic beta-Antagonists; 0/Angiotensin II Type 1 Receptor Blockers; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Cardiovascular Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The effectiveness and cost effectiveness of public-access defibrillation.
Next Document: Permanent pacemaker and implantable cardioverter defibrillator infections: seven years of diagnostic...